Your eye pressure may be at target, your injections may be on schedule, or your blood sugar may be better controlled - and yet your visual field, OCT, contrast sensitivity, night vision, or reading ability may still be declining. That does not automatically mean your treatment has failed. It means your disease, your treatment response, and the condition of the remaining visual tissue need to be reassessed carefully.
Standard ophthalmic care saves sight. Glaucoma medicines, laser procedures and surgery lower intraocular pressure. Anti-VEGF injections reduce leakage and abnormal vessel activity in wet macular degeneration, diabetic macular edema and retinal vein occlusion. Cross-linking can stabilize progressive keratoconus. Steroids and immunomodulatory treatment can control destructive ocular inflammation. These treatments should not be delayed, stopped or replaced by an alternative approach.
‍
At the same time, many chronic eye diseases are not controlled by one measurement alone. Eye pressure is the only modifiable risk factor with established treatment benefit in glaucoma, but glaucoma is still a neurodegenerative optic neuropathy. VEGF is a crucial driver of retinal leakage, but persistent fluid, fibrosis, atrophy or limited visual recovery can remain despite adequate injections. Glucose control reduces diabetic complications, but the retina may still carry years of microvascular, inflammatory and metabolic injury. When a disease keeps moving, the correct response is not to abandon standard care. It is to ask whether the diagnosis, target, timing, adherence, systemic factors and non-targeted disease mechanisms have all been examined.
Vision can fluctuate for reasons that are different from permanent disease progression. Dry eye, cataract, an outdated prescription, corneal irregularity, medication effects, fatigue, poor testing reliability and changes in lighting can all affect visual performance. Conversely, a patient may feel stable while OCT or visual-field testing shows structural or functional loss. A responsible evaluation begins by separating four questions:
Bring your longitudinal records whenever possible: OCT scans, visual fields, fundus photographs, angiography, corneal topography, pressure history, injection history, surgery reports, medication list and relevant laboratory results. A single test is a snapshot. Progression is a pattern over time.
Dry AMD should be approached as a multifactorial condition because the retina itself is a highly complex, energy-intensive, vascularly dependent, immune-active neural tissue. The macula depends on constant metabolic exchange between photoreceptors, retinal pigment epithelium, Bruch’s membrane, and the choroidal circulation. Disruption in one layer can affect the others.
A single-pathway approach is often insufficient because dry AMD involves multiple overlapping processes. Contemporary reviews describe oxidative stress, lipid dysregulation, complement activation, mitochondrial impairment, and RPE-specific lipofuscin accumulation as major mechanisms in dry AMD pathogenesis.
Glaucoma: pressure matters, but pressure is not the whole optic nerve
Lowering intraocular pressure clearly reduces the risk and rate of glaucoma progression. That is why eye drops, laser and surgery remain foundational. Yet some people progress at statistically normal pressures, and some continue to lose retinal nerve fiber layer or visual field after a meaningful pressure reduction. In those cases, the ophthalmologist may revise the target pressure, look for pressure peaks or fluctuation, verify adherence, reassess anatomy, and consider additional treatment. Researchers also study ocular perfusion, blood-pressure patterns, mitochondrial stress, excitotoxicity, glial activation and neurotrophic support as contributors to retinal ganglion-cell vulnerability.
Retinal vascular disease: controlling leakage does not erase prior injury
Anti-VEGF therapy transformed wet age-related macular degeneration and diabetic macular edema. It can reduce fluid, improve vision and prevent severe loss. However, an eye can show incomplete response, recurrent exudation, scarring, geographic or macular atrophy, ischemia, photoreceptor damage or limited functional recovery. Those outcomes may reflect advanced disease at treatment onset, undertreatment, lesion biology, chronic inflammation, vascular remodeling or irreversible damage already present. The next step is a retina-specialist reassessment - not stopping injections on your own.
Diabetic eye disease: A1C is essential, but the retina reflects cumulative vascular stress
Blood-glucose, blood-pressure and lipid management are central to diabetic retinopathy care. Even with improved numbers, however, established capillary damage, retinal ischemia, edema, inflammation and neurodegeneration may persist. Eye treatment and systemic treatment need to work together. An integrative plan should support, not compete with, diabetes management.
Inherited and degenerative disease: the target may not yet have an approved therapy
For many inherited retinal diseases, optic atrophies and degenerative disorders, monitoring and vision rehabilitation remain major parts of care because a gene-specific or disease-modifying treatment is not yet available. That reality creates a vulnerable space in which patients are often offered exaggerated claims. The ethical response is precise: identify what is treatable, screen for clinical trials, preserve function and independence, manage complications, and discuss adjunctive care without implying that it corrects the underlying mutation or reverses lost cells.
Not every factor is relevant to every person, and finding an association does not prove that treating it will change the eye disease. The point is to avoid reducing a complex visual disorder to a single number.
Netra Restoration Therapy (NRT) is Netra Eye Institute’s individualized, adjunctive program combining acupuncture, practitioner-directed herbal medicine, Ayurvedic approaches and supportive lifestyle guidance. Its clinical framework focuses on biological systems that may influence visual-tissue resilience, including ocular circulation, inflammatory regulation, oxidative stress, autonomic balance, metabolic health and neurotrophic support.
That framework is biologically plausible, but plausibility is not the same as proof. Evidence varies substantially by modality and condition. Acupuncture has a more developed evidence base for dry-eye symptoms than for glaucoma, macular degeneration or inherited retinal disease. Herbal and Ayurvedic research includes laboratory studies, small clinical studies and condition-specific trials, but product variability and study quality limit broad conclusions. NRT should therefore be presented as supportive care whose goals are individualized and measured - not as a cure, a substitute for injections or surgery, or a guarantee that progression will stop.
A realistic goal depends on the diagnosis, remaining viable tissue, rate of progression, conventional treatment status and the outcome being measured. For one patient, the goal may be improved ocular-surface comfort or reading endurance. For another, it may be better adherence, improved sleep and systemic risk-factor control. In a chronic neurodegenerative condition, the most meaningful outcome may be slower measured change over an adequate period - but that conclusion requires standardized testing and cannot be inferred from a few good days.
NRT does not replace an ophthalmologist, lower eye pressure in place of glaucoma treatment, substitute for anti-VEGF injections, reverse established retinal or optic-nerve cell loss, correct an inherited mutation, or guarantee restored 20/20 vision.
Sudden vision loss, a new curtain or shadow, many new flashes or floaters, severe eye pain, marked redness, halos with nausea, new distortion, sudden double vision, neurologic symptoms, or an abrupt increase in light sensitivity can signal an emergency. Contact your ophthalmologist, retina specialist or emergency service immediately. Do not wait for an integrative consultation.
The question is not “conventional or holistic?” The safer question is: “What has already been proven to protect this eye, what is still progressing, what additional risks are present, and what adjunctive measures can be evaluated without interrupting essential care?” Netra Eye Institute’s candidacy process should begin with diagnosis confirmation, records review, current treatment status, medication and supplement reconciliation, measurable baseline findings and realistic goals.
Request an information-first evaluation. Bring your diagnosis, recent testing and current treatment plan. Netra Eye Institute will determine whether an adjunctive program is appropriate, what outcomes can reasonably be monitored, and when referral back to an ophthalmologist or retina specialist is the priority.
Does continued vision loss mean my ophthalmologist is doing something wrong?
Not necessarily. Many eye diseases remain progressive even when care is appropriate. The first step is to confirm progression, adherence, target achievement and whether the treatment plan needs to be intensified or revised.
Should I stop eye drops or injections if they do not seem to be improving my vision?
No. Many treatments are intended to prevent additional loss rather than make vision feel better. Stopping them can allow irreversible damage. Discuss concerns directly with the prescribing ophthalmologist.
Can acupuncture or herbs restore damaged optic nerve or retinal cells?
There is no established clinical evidence that acupuncture or herbal medicine regenerates lost human retinal or optic-nerve cells. These modalities are studied as supportive approaches, and evidence differs by condition.
How will I know whether an adjunctive program is helping?
Use predefined outcomes: repeat visual fields, OCT, retinal imaging, corneal measurements, symptom questionnaires, reading performance or other condition-specific measures. Anecdotes alone cannot establish disease modification.
Can I receive NRT while continuing conventional treatment?
That is the intended model. All medications, injections, procedures and supplements should be disclosed so the plan can be coordinated safely.
Medically reviewed by Dr. Saikumar Gandapodi, DAOM, Dipl. OM, L.Ac. Â | Published: 7/1/2026 | Â Last reviewed: 7/1/2026
Want to learn more about  Netra Restoration Therapy  and holistic eye treatments or need help to schedule an appointment for a consultation?
Call us at (732) 503-9999 Â or fill out the contact us form below.
.webp)
